Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
Ascelia Pharma Secures Financing of up to SEK 35 Million
Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB